-
1.发明授权
公开(公告)号：US5424301A
公开(公告)日：1995-06-13
申请号：US12108
申请日：1993-02-01
IPC分类号： A61K9/20 , A61K31/44 , A61K47/36 , A61P25/28 , A61K31/715
CPC分类号： A61K31/44 , A61K47/36 , A61K9/2059 , Y10S514/879 , Y10S514/96 , Y10S514/97 , Y10S514/972
摘要： Solid compositions of certain cholinergic compounds are stabilized in starch. Especially compositions of corn starch combined or mixed with the 0-substituted-1,2,5,6-tetrahydro-3-pyridine oxime ether, CI-979 HCl, a cognition activator, have been found stable in a heated environment of up to 60.degree. C. over 17 days such that no losses were detected by HPLC analysis. A solid peroral pharmaceutical formulation for the treatment of cognitive disorders is based on the bicomponent composition of active ingredient and stabilizer using appropriate amounts of other excipients or components known in the formulation art.
摘要翻译： 某些胆碱能化合物的固体组合物在淀粉中稳定。 特别是与O-取代的-1,2,5,6-四氢-3-吡啶肟醚CI-979HCl，认知活化剂组合或混合的玉米淀粉的组合物已被发现在加热的环境中是稳定的 60天，17天，通过HPLC分析没有检测到损失。 用于治疗认知障碍的固体口服药物制剂基于活性成分和稳定剂的双组分组合物，其使用适当量的其它赋形剂或制剂领域已知的组分。
-
2.发明授权
公开(公告)号：US5362860A
公开(公告)日：1994-11-08
申请号：US012107
申请日：1993-02-01
CPC分类号： B82Y5/00 , A61K31/44 , A61K47/48969
摘要： A solid composition for stabilizing the dosage of cognition activator CI-979 HCl by formation of a complex with cyclic polydextrose. In particular, compositions with HP.beta.CD have been found to stabilize CI-979 HCl even in the presence of other excipients such as sodium carbonate. Pharmaceutical formulations for the treatment of cognitive disorders in humans are based on the stabilizing composition of CI-979 HCl and cyclic polydextrose, including appropriate amounts of other excipients or components as known in the formulation art.
摘要翻译： 用于通过与环状聚右旋糖形成络合物来稳定认知活化剂CI-979HCl的剂量的固体组合物。 特别地，已经发现具有HPβCD的组合物即使在其它赋形剂如碳酸钠的存在下也能稳定CI-979 HCl。 用于治疗人类认知障碍的药物制剂基于CI-979HCl和环状聚右旋糖的稳定化组合物，包括适当量的其它赋形剂或组合物，如制剂领域已知的。
-
公开(公告)号：US5200193A
公开(公告)日：1993-04-06
申请号：US600279
申请日：1990-10-22
CPC分类号： A61K9/209 , A61K31/19 , A61K9/2054 , A61K9/2059 , A61K9/2095
摘要： A pharmaceutical sustained release homogeneous tablet or homogeneous tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with a pharmaceutical active, ethylcellulose, a wicking agent, e.g. microcrystalline cellulose, an erosion promoter, e.g. pregelatinized starch, then drying and milling the granulation and blending with a dry powdered erosion promotor, wicking agent, lubricant, e.g. magnesium stearate and glidant, e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a long-lasting slow and relatively regular incremental release of the pharmaceutical active, and multi-layered pharmaceutical active tablets comprising immediate release and/or sustained release layers.
摘要翻译： 通过在醇中使用聚维酮（PVP）作为制粒流体与药物活性物质，乙基纤维素，芯吸剂例如混合物进行湿法制粒，形成药物缓释均匀片剂或均匀片剂层。 微晶纤维素，侵蚀促进剂，例如。 预胶化淀粉，然后干燥和研磨造粒并与干燥的粉末侵蚀促进剂，芯吸剂，润滑剂， 硬脂酸镁和助流剂，例如 二氧化硅，并且压制所得到的造粒物，其在施用时导致药物活性物质的长期缓慢且相对定期的增量释放，以及包含立即释放和/或持续释放层的多层药物活性片剂。
-
公开(公告)号：US5462747A
公开(公告)日：1995-10-31
申请号：US373914
申请日：1995-01-17
CPC分类号： A61K9/209 , A61K31/19 , A61K9/2054 , A61K9/2059 , A61K9/2095
摘要： A pharmaceutical sustained release homogeneous tablet or homogeneous tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with a pharmaceutical active, ethylcellulose, a wicking agent, e.g. microcrystalline cellulose, an erosion promoter, e.g. pregelatinized starch, then drying and milling the granulation and blending with a dry powdered erosion promotor, wicking agent, lubricant, e.g. magnesium stearate and glidant, e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a long-lasting slow and relatively regular incremental release of the pharmaceutical active, and multi-layered pharmaceutical active tablets comprising immediate release and/or sustained release layers.
摘要翻译： 通过在醇中使用聚维酮（PVP）作为制粒流体与药物活性物质，乙基纤维素，芯吸剂例如混合物进行湿法制粒，形成药物缓释均匀片剂或均匀片剂层。 微晶纤维素，侵蚀促进剂，例如。 预胶化淀粉，然后干燥和研磨造粒并与干燥的粉末侵蚀促进剂，芯吸剂，润滑剂， 硬脂酸镁和助流剂，例如 二氧化硅，并且压制所得到的造粒物，其在施用时导致药物活性物质的长期缓慢且相对定期的增量释放，以及包含立即释放和/或持续释放层的多层药物活性片剂。
-
公开(公告)号：US4806359A
公开(公告)日：1989-02-21
申请号：US41164
申请日：1987-04-22
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/62 , A61K31/19 , A61K47/02 , A61K47/04 , A61K47/32 , A61K47/36 , A61K47/38 , A61P29/00 , A61K9/26
CPC分类号： A61K9/209 , A61K31/19 , A61K9/2054 , A61K9/2059 , A61K9/2095
摘要： An ibuprofen-sustained release tablet or tablet layer is formed by making a wet granulation using providone (PVP) in alcohol as the granulating fluid which is mixed with ibuprofen, ethylcellulose, a wicking agent e.g. microcrystalline cellulose, an erosion promoter e.g. pregelatinized starch, then drying and milling the granulation and blending with dry powdered erosion promotor, wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a long-lasting slow and relatively regular incremental release of the ibuprofen.
-
公开(公告)号：US4851226A
公开(公告)日：1989-07-25
申请号：US214265
申请日：1988-06-30
CPC分类号： A61K9/5026 , A61K9/0056 , A61K9/5042
摘要： Chewable medicament tablets are made from coated granules of medicament wherein the coating on said granules comprises a blend of cellulose acetate or cellulose acetate butyrate and polyvinyl pyrrolidone.
摘要翻译： 可咀嚼的药物片剂由药物的包衣颗粒制成，其中所述颗粒上的包衣包含醋酸纤维素或乙酸丁酸纤维素与聚乙烯吡咯烷酮的共混物。
-
公开(公告)号：US20080166296A1
公开(公告)日：2008-07-10
申请号：US12045997
申请日：2008-03-11
申请人： Thomas N. Julian
发明人： Thomas N. Julian
CPC分类号： C07C229/76 , C07C235/60 , Y10S424/06 , Y10S514/97
摘要： Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
摘要翻译： 公开了新的药用镓组合物，包括相对于未复合的镓盐具有增加的口服生物利用度的镓络合物。 这样的组合物可用于治疗期望抑制异常升高的钙吸收的病症和疾病，包括癌症，高钙血症，骨质疏松症，骨质减少和佩吉特氏病。 还提供了制备和处理方法。
-
公开(公告)号：US07842724B2
公开(公告)日：2010-11-30
申请号：US12046128
申请日：2008-03-11
申请人： Thomas N. Julian
发明人： Thomas N. Julian
CPC分类号： C07C229/76 , C07C235/60 , Y10S424/06 , Y10S514/97
摘要： Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailability relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
摘要翻译： 公开了新的药用镓组合物，包括相对于未复合的镓盐具有增加的口服生物利用度的镓络合物。 这样的组合物可用于治疗期望抑制异常升高的钙吸收的病症和疾病，包括癌症，高钙血症，骨质疏松症，骨质减少和佩吉特氏病。 还提供了制备和处理方法。
-
公开(公告)号：US07456215B2
公开(公告)日：2008-11-25
申请号：US12045997
申请日：2008-03-11
申请人： Thomas N. Julian
发明人： Thomas N. Julian
CPC分类号： C07C229/76 , C07C235/60 , Y10S424/06 , Y10S514/97
摘要： Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
摘要翻译： 公开了新的药用镓组合物，包括相对于未复合的镓盐具有增加的口服生物利用度的镓络合物。 这样的组合物可用于治疗期望抑制异常升高的钙吸收的病症和疾病，包括癌症，高钙血症，骨质疏松症，骨质减少和佩吉特氏病。 还提供了制备和处理方法。
-
公开(公告)号：US20080160103A1
公开(公告)日：2008-07-03
申请号：US12046128
申请日：2008-03-11
申请人： Thomas N. Julian
发明人： Thomas N. Julian
CPC分类号： C07C229/76 , C07C235/60 , Y10S424/06 , Y10S514/97
摘要： Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.033 秒)
